Načítá se...
Pirfenidone treatment in idiopathic pulmonary fibrosis: nationwide Danish results
BACKGROUND: Pirfenidone was approved by the European Medicines Agency and introduced in most European countries in 2011 for treatment of idiopathic pulmonary fibrosis (IPF). OBJECTIVE: To describe the national Danish experiences of pirfenidone treatment for IPF during 30 months with respect to targe...
Uloženo v:
| Vydáno v: | Eur Clin Respir J |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Co-Action Publishing
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5018656/ https://ncbi.nlm.nih.gov/pubmed/27616539 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3402/ecrj.v3.32608 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|